SS Innovations International (NASDAQ: SSII) has announced the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo, utilizing the SSi Mantra 3.0 surgical robotic system. This development represents a significant step forward in the adoption of robotic-assisted cardiac surgery in South Asia and underscores the company's expanding international presence in the surgical robotics market.
The program's inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. The LIMA takedown is a critical step in coronary artery bypass grafting, and performing it robotically offers the potential for enhanced precision and reduced trauma compared to traditional open surgery. The successful completion of this procedure signals the beginning of a new era in cardiac care for Sri Lanka.
According to a recent company video describing the program's early activity, Kings Hospital has already completed more than 25 robotic procedures in just three weeks. This rapid adoption rate suggests strong local demand and confidence in the SSi Mantra system, as well as the effectiveness of the training and support provided by SS Innovations. The swift uptake also demonstrates the potential for robotic surgery to become a standard part of cardiac care in the region.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter, reflecting the company's growing global reach. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, pointing to rising utilization of the company's installed base. These figures indicate that not only is the company expanding its footprint, but also that existing systems are being used more frequently, which is a key driver of long-term recurring revenue and market penetration.
The next major corporate milestone is regulatory expansion, with SS Innovations pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open up the world's largest healthcare markets, potentially accelerating the company's growth trajectory and further validating its technology. The successful launch in Sri Lanka adds to the company's credentials as it seeks to compete with established players in the surgical robotics field.
The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer
